Patents by Inventor Ahma Hewet

Ahma Hewet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acids encoding modified relaxin polypeptides
    Patent number: 9452222
    Abstract: Modified relaxin polypeptides and their uses thereof are provided.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: September 27, 2016
    Assignee: AMBRX, INC.
    Inventors: Vadim Kraynov, Nick Knudsen, Ahma Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
  • Modified Relaxin Polypeptides and Their Uses
    Publication number: 20140194357
    Abstract: Modified relaxin polypeptides and their uses thereof are provided
    Type: Application
    Filed: January 10, 2014
    Publication date: July 10, 2014
    Applicant: AMBRX, INC.
    Inventors: VADIM KRAYNOV, NICK KNUDSEN, AHMA HEWET, KRISTINE DE DIOS, JASON PINKSTAFF, LORRAINE SULLIVAN
  • Relaxin polypeptides comprising non-naturally encoded amino acids
    Patent number: 8735539
    Abstract: Modified relaxin polypeptides and their uses are provided. In one aspect, the disclosure provides a relaxin polypeptide comprising one or more non-naturally encoded amino acids. The polypeptide may be linked to a linker, polymer, or biologically active molecule. The serum half-life of the relaxin polypeptide may be enhanced relative to the unconjugated form. In another aspect, the disclosure provides methods of treating a patient having a disorder modulated by relaxin.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: May 27, 2014
    Assignee: Ambrx, Inc.
    Inventors: Vadim Kraynov, Nick Knudsen, Ahma Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
  • Relaxin polypeptides comprising non-naturally encoded amino acids
    Patent number: 8691940
    Abstract: Modified relaxin polypeptides and their uses are provided. In one aspect, the disclosure provides a relaxin polypeptide comprising one or more non-naturally encoded amino acids. The polypeptide may be linked to a linker, polymer, or biologically active molecule. The serum half-life of the relaxin polypeptide may be enhanced relative to the unconjugated form. In another aspect, the disclosure provides methods of treating a patient having a disorder modulated by relaxin.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: April 8, 2014
    Assignee: Ambrx, Inc.
    Inventors: Vadim Kraynov, Nick Knudsen, Ahma Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan